Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea

Escherichia Coli Infection Clinical Trial

Official title:

A Phase 1 Dose-Escalating Study of dscCfaE, Co-Administered With and Without LTR192G, by Transcutaneous Immunization (TCI) in Healthy Adult U.S. Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01382095
• Other study ID #: A-16682
• Secondary ID: NMRC.2011.0004WR
• Status: Completed
• Phase: Phase 1
• First received: June 23, 2011
• Last updated: April 24, 2015
• Start date: July 2011
• Est. completion date: April 2013

Study information

• Verified date: April 2015
• Source: U.S. Army Medical Research and Materiel Command
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to determine if immunization with a recombinant E. coli protein, dscCfaE, is safe and immunogenic when administered through the skin using a patch.

Description:

The purpose of the study is to determine if immunization with dscCfaE with or without a modified E. coli heat labile enterotoxin, LTR192G, is safe and immunogenic when administered transcutaneously using a skin wet-patch. If the vaccine is found safe and adequately immunogenic in humans, a phase 2b vaccination/challenge study would be undertaken to further evaluate vaccine safety and allow a preliminary assessment of efficacy. With favorable evidence for safety, immunogenicity, efficacy, complemented by advances in standard methodology to combine multiple adhesins with an appropriate LT enterotoxoid form, a multivalent vaccine would be constructed and evaluated for further clinical development.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: April 2013
• Est. primary completion date: August 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Healthy, adult, male or female, age 18 to 45 years (inclusive) at the time of enrollment.

• Completion and review of comprehension test (achieved > 70% accuracy).

• Signed informed consent document.

• Available for the required follow-up period and scheduled clinic visits.

• Women: Negative pregnancy test with understanding (through informed consent process) to not become pregnant during the study or within three (3) months following study completion.

Exclusion Criteria:

• Health problems such as, chronic medical conditions such as psychiatric conditions, diabetes mellitus, hypertension or any other conditions that might place the volunteer at increased risk of adverse events. Study clinicians, in consultation with the principal investigator (PI), will use clinical judgment on a case-by-case basis to assess safety risks under this criterion. The PI will consult with the Medical Monitor as appropriate.

• Clinically significant abnormalities on physical examination.

• Immunosuppressive drugs (use of systemic corticosteroids or chemotherapeutics that may influence antibody development) or illness (including IgA deficiency).

• Women who are pregnant or planning to become pregnant during the study period plus 3 months beyond the last study safety visit and currently nursing women.

• Participation in research involving another investigational product (defined as receipt of investigational product or exposure to invasive investigational device) 30 days before planned date of first vaccination or anytime through the last study safety visit.

• Positive blood test for HBsAg, HCV, HIV-1.

• Clinically significant abnormalities on basic laboratory screening.

• Immunosuppressive illness or IgA deficiency (below the normal limits).

• Exclusionary skin history/findings that would confound assessment or prevent appropriate local monitoring of adverse events (AEs), or possibly increase the risk of an AE.

• History of chronic skin disease (clinician judgment).

• History of atopy.

• Acute skin infection/eruptions on the upper arms including fungal infections, severe acne or active contact dermatitis.

• Allergies that may increase the risk of AEs.

• Regular use (weekly or more often) of antidiarrheal, anti-constipation, or antacid therapy.

• Abnormal stool pattern (fewer than 3 stools per week or more than 3 stools per day) on a regular basis; loose or liquid stools on other than an occasional basis.

• History of microbiologically confirmed Enterotoxigenic E. coli (ETEC) or V. cholerae infection.

• Travel to countries where ETEC or V. cholerae or other enteric infections are endemic (most of the developing world) within two years prior to dosing (clinician judgment).

• Received previous experimental ETEC or V. cholerae vaccine or live ETEC or V. cholerae challenge.

• Occupation involving handling of ETEC or V. cholerae currently, or in the past 3 years.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Escherichia Coli Infection
• Escherichia coli Infections

Intervention

Biological:
• Recombinant fimbrial adhesin dscCfaE
10 ug on study days 0, 21 and 42
• Recombinant fimbrial adhesin dscCfaE
50 ug on study days 0, 21 and 42
• Recombinant fimbrial adhesin dscCfaE
250 ug on study days 0, 21 and 42
• Modified E. coli heat labile enterotoxin LTR192G
50 ug on study days 0, 21 and 42

Locations

Country	Name	City	State
United States	Walter Reed Army Institute of Research Clinical Trial Center	Silver Spring	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
U.S. Army Medical Research and Materiel Command

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of adverse events	Adverse event monitoring will survey and specifically inquire about fever (oral temperature > 100.4 o F), malaise, headache, rash, pain, diarrhea, abdominal pain, extremity pain or swelling. Clinical definitions will be used to grade severity of symptoms in accordance to the severity scale below: Grade 0 = None Grade 1= Barely noticeable Grade 2= Noticeable, does not interfere with daily activities Grade 3=Interferes with daily activities Grade 4=Prevents daily activities	Days 0 - 180	Yes
Secondary	Number of Seroconversion to LT and dscCfaE; defined as a > 4-fold increase in endpoint titer between pre-and post-vaccination samples.		Study Days 0 - 180	No
Secondary	Number of Mucosal responses (fecal IgA); defined as a > 4-fold increase in endpoint titer after adjusting for total IgA.		Study Days 0 - 180	No
Secondary	Number of positive IgA-ASC responses; defined as a > 2-fold increase over th e baseline value of the ASC per 10 6 PBMC, when the number of ASC is > 0.5 per 10 6 in the baseline sample	A positive IgA-ASC response will be defined as a > 2-fold increase over th e baseline value of the ASC per 10 6 PBMC, when the number of ASC is > 0.5 per 10 6 in the baseline sample. When the number of baseline ASCs is less than 0.5 per 10 6 PBMC, a subject will be considered a responder if the post-vaccination value is greater than 1.0 per 10 6 PBMC	Study Days 0 - 180	No